Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iberdomide in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
NCT05560399Phase 1Active, not recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Feb 2023
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iberdomide in multiple myeloma (MM), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Feb 2023; status: active, not recruiting.
02
Drugs
iberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05560399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05560399.